Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Stage IIIB (with confirmed malignant pleural effusion), stage IV, or recurrent disease * Mixed tumors categorized by the predominant cell type are allowed provided no small cell elements exist * Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy * Measurable disease as defined by RECIST criteria * No squamous cell carcinoma (group 1) * No history of brain metastases (group 1) * History of treated brain metastases allowed provided patient is not taking steroids and anti-seizure mediation (group 2) PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 1.5 mg/dL * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN with liver metastases) * AST and ALT ≤ 3 times ULN (≤ 5 times ULN with liver metastases) * INR \< 1.5 or PTT normal (group 1) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during (groups 1 and 2) and for 6 months after completion of study treatment (group 1) * No preexisting peripheral neuropathy ≥ grade 2 * Must be able to swallow tablets * No cardiovascular condition, including any of the following: * Myocardial infarction within the past 6 months * Cerebrovascular ischemia or stroke within the past 6 months * NYHA congestive heart failure \> class II * Unstable angina pectoris * Serious cardiac arrhythmia requiring medication * Significant vascular disease * Symptomatic peripheral vascular disease * No concurrent medical condition, psychiatric illness, or limitations that would limit study compliance * No ongoing active infection or ongoing fever within the past 6 months * No history of uncontrolled hypertension, defined as blood pressure ≥ 150/90 mm Hg despite being on a stable regimen of anti-hypertensive therapy * No serious nonhealing wound, ulcer, or bone fracture within the past 4 weeks * No ongoing or active infection * No history of thrombotic or hemorrhagic disorders, bleeding diathesis, or coagulopathy (group 1) * No bleeding \> grade 2 or any bleeding requiring intervention within the past 4 weeks (group 1) * No history of gross hemoptysis (defined as \> ½ teaspoon of bright red blood) (group 1) * Urine protein:creatinine (UPC) ratio \< 1.0 by spot urinalysis * For UPC ratio \> 0.5, a 24-hour urine protein must be obtained and the urine protein level must be \< 1,000 mg (group 1) * None of the following conditions (group 1): * Grade II or greater peripheral vascular disease * Abdominal fistula * Gastrointestinal perforation * Intra-abdominal abscess * No known hypersensitivity to any component of bevacizumab (group 1) * No history of hypertensive crisis or hypertensive encephalopathy (group 1) PRIOR CONCURRENT THERAPY: * More than 4 weeks since prior major surgical procedure * More than 7 days since prior minor surgical procedure * No prior chemotherapy for advanced NSCLC * Postoperative adjuvant chemotherapy for previously resected NSCLC allowed if last dose was given \> 1 year ago * More than 3 weeks since prior radiation therapy and recovered * More than 3 weeks since prior immunotherapy and/or hormonal therapy (not including hormone replacement therapy or contraceptives) and recovered * More than 14 days since prior enzyme inducing anti-epileptic drugs (EIAEDs) * More than 10 days since prior and no concurrent daily treatment with acetylsalicylic acid (\> 325 mg/day) or NSAIDs known to inhibit platelet function for chronic conditions (group 1) * No concurrent major surgical procedure (group 1) * No concurrent carbamazepine, phenobarbital, or phenytoin * No concurrent therapeutic anticoagulation (group 1) * Prophylactic anticoagulation of venous access devices is allowed * No concurrent treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol (group 1) * No concurrent combination antiretroviral therapy for HIV-positive patients